Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Puma Biotechnology's operating cash flow for the twelve months ending Jun 30, 2026 was $41.15M, down 7.2% year over year. For fiscal 2025 it was $41.80M, up 7.4% from the year before. The highest annual figure on record is $41.80M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.80M | +7.4% |
| FY2024 | Dec 31, 2024 | $38.92M | +44.1% |
| FY2023 | Dec 31, 2023 | $27.01M | – |
| FY2022 | Dec 31, 2022 | -$15.83M | -176.6% |
| FY2021 | Dec 31, 2021 | $20.65M | +2571.4% |
| FY2020 | Dec 31, 2020 | $773.00K | -96.5% |
| FY2019 | Dec 31, 2019 | $22.38M | – |
| FY2018 | Dec 31, 2018 | -$24.11M | – |
| FY2017 | Dec 31, 2017 | -$172.47M | – |
| FY2016 | Dec 31, 2016 | -$141.69M | – |
| FY2015 | Dec 31, 2015 | -$154.47M | – |
| FY2014 | Dec 31, 2014 | -$77.20M | – |
| FY2013 | Dec 31, 2013 | -$55.05M | – |
| FY2012 | Dec 31, 2012 | -$44.01M | – |
| FY2011 | Dec 31, 2011 | -$1.82M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.62M | -88.5% |
| Q1 FY2026 | Mar 31, 2026 | $15.42M | +326.8% |
| Q4 FY2025 | Dec 31, 2025 | $14.42M | -7.6% |
| Q3 FY2025 | Sep 30, 2025 | $9.69M | -12.2% |
| Q2 FY2025 | Jun 30, 2025 | $14.08M | +1271.2% |
| Q1 FY2025 | Mar 31, 2025 | $3.61M | -67.9% |
| Q4 FY2024 | Dec 31, 2024 | $15.61M | +49.3% |
| Q3 FY2024 | Sep 30, 2024 | $11.04M | +4.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.03M | -68.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.25M | +325.5% |
| Q4 FY2023 | Dec 31, 2023 | $10.46M | +36.1% |
| Q3 FY2023 | Sep 30, 2023 | $10.62M | -38.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.30M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.64M | – |
| Q4 FY2022 | Dec 31, 2022 | $7.68M | – |
| Q3 FY2022 | Sep 30, 2022 | $17.26M | +64.4% |
| Q2 FY2022 | Jun 30, 2022 | -$13.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.90M | -271.7% |
| Q4 FY2021 | Dec 31, 2021 | -$5.44M | – |
| Q3 FY2021 | Sep 30, 2021 | $10.50M | +510.3% |
| Q2 FY2021 | Jun 30, 2021 | -$74.00K | -100.5% |
| Q1 FY2021 | Mar 31, 2021 | $15.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.64M | -459.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.72M | – |
| Q2 FY2020 | Jun 30, 2020 | $16.23M | -63.3% |
| Q1 FY2020 | Mar 31, 2020 | -$11.54M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.57M | -77.8% |
| Q3 FY2019 | Sep 30, 2019 | -$7.31M | – |
| Q2 FY2019 | Jun 30, 2019 | $44.25M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.13M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.26M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.64M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$35.61M | – |
| Q3 FY2017 | Sep 30, 2017 | -$54.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$45.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$36.04M | – |
| Q4 FY2016 | Dec 31, 2016 | -$40.96M | – |
| Q3 FY2016 | Sep 30, 2016 | -$34.89M | – |
See a number that looks wrong?